 | • レポートコード：MRC309Z7097 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の遺伝子治療ウイルスベクター&プラスミドDNAの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の遺伝子治療ウイルスベクター&プラスミドDNA市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 遺伝子治療ウイルスベクター&プラスミドDNAの成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 遺伝子治療ウイルスベクター&プラスミドDNA市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・ウイルスベクター、プラスミドDNA 用途別セグメント ・細胞&遺伝子治療、ワクチン開発、研究 主要な市場プレーヤー ・Lonza、Merck KGaA、Thermo Fisher Scientific、Charles River Laboratories、Catalent、WuXi AppTec、FUJIFILM、GenScript Biotech、Takara Bio、Oxford Biomedica、Novartis、Precision Biosciences、Bluebird Bio、Sartorius AG、Danaher、SIRON Biotech、VGXI、Waisman Biomanufacturing、Kaneka Eurogentec、PlasmidFactory、ATUM、Addgene、Cell and Gene Therapy Catapult、Batavia biosciences、Altogen Biosystems 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、遺伝子治療ウイルスベクター&プラスミドDNA製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な遺伝子治療ウイルスベクター&プラスミドDNAメーカーの企業概要、2019年～2022年までの遺伝子治療ウイルスベクター&プラスミドDNAの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な遺伝子治療ウイルスベクター&プラスミドDNAメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別遺伝子治療ウイルスベクター&プラスミドDNAの販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの遺伝子治療ウイルスベクター&プラスミドDNAの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での遺伝子治療ウイルスベクター&プラスミドDNA市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および遺伝子治療ウイルスベクター&プラスミドDNAの産業チェーンを掲載しています。 ・第14、15章では、遺伝子治療ウイルスベクター&プラスミドDNAの販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 遺伝子治療ウイルスベクター&プラスミドDNAの概要 - 種類別分析（2018年vs2022年vs2029年）：ウイルスベクター、プラスミドDNA - 用途別分析（2018年vs2022年vs2029年）：細胞&遺伝子治療、ワクチン開発、研究 - 世界の遺伝子治療ウイルスベクター&プラスミドDNA市場規模・予測 - 世界の遺伝子治療ウイルスベクター&プラスミドDNA生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Lonza、Merck KGaA、Thermo Fisher Scientific、Charles River Laboratories、Catalent、WuXi AppTec、FUJIFILM、GenScript Biotech、Takara Bio、Oxford Biomedica、Novartis、Precision Biosciences、Bluebird Bio、Sartorius AG、Danaher、SIRON Biotech、VGXI、Waisman Biomanufacturing、Kaneka Eurogentec、PlasmidFactory、ATUM、Addgene、Cell and Gene Therapy Catapult、Batavia biosciences、Altogen Biosystems ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：ウイルスベクター、プラスミドDNA ・用途別分析2018年-2029年：細胞&遺伝子治療、ワクチン開発、研究 ・遺伝子治療ウイルスベクター&プラスミドDNAの北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・遺伝子治療ウイルスベクター&プラスミドDNAのヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・遺伝子治療ウイルスベクター&プラスミドDNAのアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・遺伝子治療ウイルスベクター&プラスミドDNAの南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・遺伝子治療ウイルスベクター&プラスミドDNAの中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Gene Therapy Viral Vector and Plasmid DNA market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors.
This report is a detailed and comprehensive analysis for global Gene Therapy Viral Vector and Plasmid DNA market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Gene Therapy Viral Vector and Plasmid DNA market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Gene Therapy Viral Vector and Plasmid DNA market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Gene Therapy Viral Vector and Plasmid DNA market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Gene Therapy Viral Vector and Plasmid DNA market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Therapy Viral Vector and Plasmid DNA
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Therapy Viral Vector and Plasmid DNA market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories and Catalent, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Gene Therapy Viral Vector and Plasmid DNA market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Viral Vectors
Plasmid DNA
Market segment by Application
Cell and Gene Therapy
Vaccine Development
Research
Major players covered
Lonza
Merck KGaA
Thermo Fisher Scientific
Charles River Laboratories
Catalent
WuXi AppTec
FUJIFILM
GenScript Biotech
Takara Bio
Oxford Biomedica
Novartis
Precision Biosciences
Bluebird Bio
Sartorius AG
Danaher
SIRON Biotech
VGXI
Waisman Biomanufacturing
Kaneka Eurogentec
PlasmidFactory
ATUM
Addgene
Cell and Gene Therapy Catapult
Batavia biosciences
Altogen Biosystems
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Gene Therapy Viral Vector and Plasmid DNA product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gene Therapy Viral Vector and Plasmid DNA, with price, sales, revenue and global market share of Gene Therapy Viral Vector and Plasmid DNA from 2018 to 2023.
Chapter 3, the Gene Therapy Viral Vector and Plasmid DNA competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gene Therapy Viral Vector and Plasmid DNA breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Gene Therapy Viral Vector and Plasmid DNA market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gene Therapy Viral Vector and Plasmid DNA.
Chapter 14 and 15, to describe Gene Therapy Viral Vector and Plasmid DNA sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Gene Therapy Viral Vector and Plasmid DNA
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Viral Vectors
1.3.3 Plasmid DNA
1.4 Market Analysis by Application
1.4.1 Overview: Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cell and Gene Therapy
1.4.3 Vaccine Development
1.4.4 Research
1.5 Global Gene Therapy Viral Vector and Plasmid DNA Market Size & Forecast
1.5.1 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (2018-2029)
1.5.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.1.4 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Lonza Recent Developments/Updates
2.2 Merck KGaA
2.2.1 Merck KGaA Details
2.2.2 Merck KGaA Major Business
2.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.2.4 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck KGaA Recent Developments/Updates
2.3 Thermo Fisher Scientific
2.3.1 Thermo Fisher Scientific Details
2.3.2 Thermo Fisher Scientific Major Business
2.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.3.4 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Thermo Fisher Scientific Recent Developments/Updates
2.4 Charles River Laboratories
2.4.1 Charles River Laboratories Details
2.4.2 Charles River Laboratories Major Business
2.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.4.4 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Charles River Laboratories Recent Developments/Updates
2.5 Catalent
2.5.1 Catalent Details
2.5.2 Catalent Major Business
2.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.5.4 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Catalent Recent Developments/Updates
2.6 WuXi AppTec
2.6.1 WuXi AppTec Details
2.6.2 WuXi AppTec Major Business
2.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.6.4 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 WuXi AppTec Recent Developments/Updates
2.7 FUJIFILM
2.7.1 FUJIFILM Details
2.7.2 FUJIFILM Major Business
2.7.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.7.4 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 FUJIFILM Recent Developments/Updates
2.8 GenScript Biotech
2.8.1 GenScript Biotech Details
2.8.2 GenScript Biotech Major Business
2.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.8.4 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GenScript Biotech Recent Developments/Updates
2.9 Takara Bio
2.9.1 Takara Bio Details
2.9.2 Takara Bio Major Business
2.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.9.4 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Takara Bio Recent Developments/Updates
2.10 Oxford Biomedica
2.10.1 Oxford Biomedica Details
2.10.2 Oxford Biomedica Major Business
2.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.10.4 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Oxford Biomedica Recent Developments/Updates
2.11 Novartis
2.11.1 Novartis Details
2.11.2 Novartis Major Business
2.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.11.4 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Novartis Recent Developments/Updates
2.12 Precision Biosciences
2.12.1 Precision Biosciences Details
2.12.2 Precision Biosciences Major Business
2.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.12.4 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Precision Biosciences Recent Developments/Updates
2.13 Bluebird Bio
2.13.1 Bluebird Bio Details
2.13.2 Bluebird Bio Major Business
2.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.13.4 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bluebird Bio Recent Developments/Updates
2.14 Sartorius AG
2.14.1 Sartorius AG Details
2.14.2 Sartorius AG Major Business
2.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.14.4 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Sartorius AG Recent Developments/Updates
2.15 Danaher
2.15.1 Danaher Details
2.15.2 Danaher Major Business
2.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.15.4 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Danaher Recent Developments/Updates
2.16 SIRON Biotech
2.16.1 SIRON Biotech Details
2.16.2 SIRON Biotech Major Business
2.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.16.4 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 SIRON Biotech Recent Developments/Updates
2.17 VGXI
2.17.1 VGXI Details
2.17.2 VGXI Major Business
2.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.17.4 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 VGXI Recent Developments/Updates
2.18 Waisman Biomanufacturing
2.18.1 Waisman Biomanufacturing Details
2.18.2 Waisman Biomanufacturing Major Business
2.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.18.4 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Waisman Biomanufacturing Recent Developments/Updates
2.19 Kaneka Eurogentec
2.19.1 Kaneka Eurogentec Details
2.19.2 Kaneka Eurogentec Major Business
2.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.19.4 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Kaneka Eurogentec Recent Developments/Updates
2.20 PlasmidFactory
2.20.1 PlasmidFactory Details
2.20.2 PlasmidFactory Major Business
2.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.20.4 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 PlasmidFactory Recent Developments/Updates
2.21 ATUM
2.21.1 ATUM Details
2.21.2 ATUM Major Business
2.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.21.4 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 ATUM Recent Developments/Updates
2.22 Addgene
2.22.1 Addgene Details
2.22.2 Addgene Major Business
2.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.22.4 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Addgene Recent Developments/Updates
2.23 Cell and Gene Therapy Catapult
2.23.1 Cell and Gene Therapy Catapult Details
2.23.2 Cell and Gene Therapy Catapult Major Business
2.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.23.4 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 Cell and Gene Therapy Catapult Recent Developments/Updates
2.24 Batavia biosciences
2.24.1 Batavia biosciences Details
2.24.2 Batavia biosciences Major Business
2.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.24.4 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.24.5 Batavia biosciences Recent Developments/Updates
2.25 Altogen Biosystems
2.25.1 Altogen Biosystems Details
2.25.2 Altogen Biosystems Major Business
2.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.25.4 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.25.5 Altogen Biosystems Recent Developments/Updates
3 Competitive Environment: Gene Therapy Viral Vector and Plasmid DNA by Manufacturer
3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Manufacturer (2018-2023)
3.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Manufacturer (2018-2023)
3.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Gene Therapy Viral Vector and Plasmid DNA by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Gene Therapy Viral Vector and Plasmid DNA Manufacturer Market Share in 2022
3.4.2 Top 6 Gene Therapy Viral Vector and Plasmid DNA Manufacturer Market Share in 2022
3.5 Gene Therapy Viral Vector and Plasmid DNA Market: Overall Company Footprint Analysis
3.5.1 Gene Therapy Viral Vector and Plasmid DNA Market: Region Footprint
3.5.2 Gene Therapy Viral Vector and Plasmid DNA Market: Company Product Type Footprint
3.5.3 Gene Therapy Viral Vector and Plasmid DNA Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Size by Region
4.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2029)
4.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2029)
4.1.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Region (2018-2029)
4.2 North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.3 Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.4 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.5 South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.6 Middle East and Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
5.2 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
5.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
6.2 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
6.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Application (2018-2029)
7 North America
7.1 North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
7.2 North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
7.3 North America Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
7.3.1 North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
7.3.2 North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
8.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
8.3 Europe Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
8.3.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
8.3.2 Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Market Size by Region
9.3.1 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
10.2 South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
10.3 South America Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
10.3.1 South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
10.3.2 South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
11.3.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Gene Therapy Viral Vector and Plasmid DNA Market Drivers
12.2 Gene Therapy Viral Vector and Plasmid DNA Market Restraints
12.3 Gene Therapy Viral Vector and Plasmid DNA Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Gene Therapy Viral Vector and Plasmid DNA and Key Manufacturers
13.2 Manufacturing Costs Percentage of Gene Therapy Viral Vector and Plasmid DNA
13.3 Gene Therapy Viral Vector and Plasmid DNA Production Process
13.4 Gene Therapy Viral Vector and Plasmid DNA Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Gene Therapy Viral Vector and Plasmid DNA Typical Distributors
14.3 Gene Therapy Viral Vector and Plasmid DNA Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer